Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hormel Foods Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Hormel securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Recent Developments - On October 29, 2025, The Wall Street Journal reported that Hormel cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility, leading to a 9.1% drop in stock price [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being ranked highly for its performance in this area [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of James Hardie Industries plc during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought James Hardie common stock between May 20, 2025, and August 18, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 23, 2025 [3][5]. - The lawsuit alleges that James Hardie misled investors regarding the strength of its North America Fiber Cement segment, claiming demand was strong while distributors were actually destocking inventory [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6] Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases driven by cytokines IL-17A and IL-17F [3][4] Trial Results and Market Reaction - The Phase 3 trials for SLK revealed that only one of the two trials achieved statistical significance, with results showing substantially lower efficacy compared to the competitor's FDA-approved product, BIMZELX [6] - Following the announcement, MoonLake's share price plummeted by $55.75, or about 90%, on September 29, 2025 [2][6] Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK's Nanobody structure over traditional monoclonal antibodies [5][6] - Specific allegations include misleading claims about the clinical benefits of SLK compared to BIMZELX, including the assertion that SLK's structure would provide superior clinical efficacy [5] Legal Proceedings - The class action lawsuit is focused on the propriety of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3][5] - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Tronox Holdings plc common stock of the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for investors who bought shares during the specified period [1][2]. Group 1: Class Action Details - The class action pertains to investors who purchased Tronox common stock between February 12, 2025, and July 30, 2025, with a lead plaintiff deadline set for November 3, 2025 [1][2]. - Investors can join the class action without incurring out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success and recognition in this field [3]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [3]. Group 3: Case Allegations - The lawsuit alleges that Tronox's management made misleading statements regarding the company's growth and performance in its pigment and zircon commercial division, which ultimately led to a failure in meeting revenue projections [4]. - It is claimed that while positive statements were made to investors, there were material adverse facts being concealed about the company's ability to forecast demand and manage costs, resulting in investor damages when the truth was revealed [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Tandem Diabetes Care on August 7, 2025, announcing a voluntary medical device correction for select t:slim X2 insulin pumps, which could lead to a discontinuation of insulin delivery [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1 - The investigation is focused on the potential impact of misleading information on the investing public [1] - Shareholders who purchased Soleno Therapeutics securities may be entitled to compensation without any out-of-pocket fees or costs [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Coty, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Financial Performance - Coty disclosed its financial results for the full fiscal year of 2025 and its fourth quarter in a Current Report on Form 8-K filed on August 20, 2025 [3]. - The Chief Financial Officer of Coty attributed sluggish sales to several factors, including value-seeking behavior, innovation fatigue among consumers, and changes in anti-theft and immigration policies [3]. Group 2: Stock Market Reaction - Following the news of Coty's financial performance, the company's stock price fell by $1.05 per share, representing a decline of 21.6%, closing at $3.81 per share on August 21, 2025 [4]. Group 3: Legal Action and Investor Rights - Investors who purchased Coty securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of CarMax, Inc. due to allegations of materially misleading business information issued by the company [1]. Financial Performance - CarMax reported earnings per share (EPS) of $0.64 on $6.6 billion in sales for the second quarter of its 2026 fiscal year, significantly below consensus estimates of EPS of $1.03 on $7 billion in sales [4]. - The CEO described the quarter as "challenging" and announced a plan to cut selling, general, and administrative spending by $150 million over the next 18 months [4]. Stock Market Reaction - Following the disappointing financial results, CarMax's stock price fell by $11.5 per share, or 20.07%, closing at $45.60 per share on September 25, 2025 [5]. Legal Action - Rosen Law Firm is preparing a class action lawsuit seeking recovery of investor losses, allowing affected shareholders to join without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [3]. Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [6].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Company Details - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries [4] - The misleading statements led to investors suffering damages when the true details were revealed [4] Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [3]